Key Analysts at Deutsche Bank Reconfirmed their ‘Buy’ rating for Impax Laboratories (NASDAQ:IPXL) Shares Today. Their TP Given is $21

July 17, 2017 - By reb123z

 Key Analysts at Deutsche Bank Reconfirmed their ‘Buy’ rating for Impax Laboratories (NASDAQ:IPXL) Shares Today. Their TP Given is $21

Investors sentiment decreased to 1.18 in 2016 Q4. Its down 0.25, from 1.43 in 2016Q3. It dropped, as 31 investors sold Impax Laboratories Inc shares while 51 reduced holdings. 36 funds opened positions while 61 raised stakes. 57.71 million shares or 5.44% less from 61.03 million shares in 2016Q3 were reported.

Fifth Third Commercial Bank holds 0% or 390 shares in its portfolio. Ahl Ptnrs Llp reported 0.01% stake. Lsv Asset Management stated it has 24,100 shares. North Tide Llc holds 4.53% or 2.00 million shares in its portfolio. Cornerstone Capital Mgmt Hldgs Ltd Liability Company stated it has 0.02% in Impax Laboratories Inc (NASDAQ:IPXL). State Of Alaska Department Of Revenue reported 0.01% in Impax Laboratories Inc (NASDAQ:IPXL). State Teachers Retirement Sys invested in 103,960 shares. Jacobs Levy Equity Mgmt Inc has invested 0.05% in Impax Laboratories Inc (NASDAQ:IPXL). Franklin reported 2.17 million shares or 0.01% of all its holdings. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 2,360 shares. Moreover, Public Employees Retirement Association Of Colorado has 0% invested in Impax Laboratories Inc (NASDAQ:IPXL). Acadian Asset Ltd Liability reported 0% in Impax Laboratories Inc (NASDAQ:IPXL). Alliancebernstein L P accumulated 125,749 shares. Federated Investors Pa accumulated 286,955 shares. 39,187 are held by Blackrock Advsrs Ltd Liability Corporation.

Since May 12, 2017, it had 0 buys, and 3 insider sales for $43,046 activity.

Impax Laboratories (NASDAQ:IPXL) Rating Reaffirmed

Deutsche Bank now has a $21 target price per share on shares of Impax Laboratories (NASDAQ:IPXL). The target price per share suggests a potential upside of 15.58 % from the previous stock close of Impax Laboratories (NASDAQ:IPXL). This rating was disclosed in a note on 17 July.

Investors sentiment decreased to 1.18 in 2016 Q4. Its down 0.25, from 1.43 in 2016Q3. It dropped, as 31 investors sold Impax Laboratories Inc shares while 51 reduced holdings. 36 funds opened positions while 61 raised stakes. 57.71 million shares or 5.44% less from 61.03 million shares in 2016Q3 were reported.

Fifth Third Commercial Bank holds 0% or 390 shares in its portfolio. Ahl Ptnrs Llp reported 0.01% stake. Lsv Asset Management stated it has 24,100 shares. North Tide Llc holds 4.53% or 2.00 million shares in its portfolio. Cornerstone Capital Mgmt Hldgs Ltd Liability Company stated it has 0.02% in Impax Laboratories Inc (NASDAQ:IPXL). State Of Alaska Department Of Revenue reported 0.01% in Impax Laboratories Inc (NASDAQ:IPXL). State Teachers Retirement Sys invested in 103,960 shares. Jacobs Levy Equity Mgmt Inc has invested 0.05% in Impax Laboratories Inc (NASDAQ:IPXL). Franklin reported 2.17 million shares or 0.01% of all its holdings. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 2,360 shares. Moreover, Public Employees Retirement Association Of Colorado has 0% invested in Impax Laboratories Inc (NASDAQ:IPXL). Acadian Asset Ltd Liability reported 0% in Impax Laboratories Inc (NASDAQ:IPXL). Alliancebernstein L P accumulated 125,749 shares. Federated Investors Pa accumulated 286,955 shares. 39,187 are held by Blackrock Advsrs Ltd Liability Corporation.

Since May 12, 2017, it had 0 buys, and 3 insider sales for $43,046 activity.

Impax Laboratories Inc (NASDAQ:IPXL) Ratings Coverage

Among 15 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 4 have Buy rating, 2 Sell and 9 Hold. Therefore 27% are positive. Impax Laboratories Inc. has $60 highest and $1500 lowest target. $29.46’s average target is 62.14% above currents $18.17 stock price. Impax Laboratories Inc. had 24 analyst reports since July 21, 2015 according to SRatingsIntel. As per Wednesday, June 29, the company rating was initiated by BMO Capital Markets. Janney Capital initiated the stock with “Neutral” rating in Wednesday, December 28 report. As per Friday, July 14, the company rating was maintained by RBC Capital Markets. The firm has “Buy” rating by BTIG Research given on Tuesday, October 6. Deutsche Bank maintained the stock with “Hold” rating in Wednesday, August 10 report. The firm earned “Outperform” rating on Monday, August 15 by Northland Capital. The rating was initiated by Goldman Sachs on Monday, June 6 with “Sell”. On Tuesday, September 29 the stock rating was initiated by Nomura with “Neutral”. The firm earned “Hold” rating on Monday, June 12 by RBC Capital Markets. On Wednesday, January 6 the stock rating was initiated by JP Morgan with “Neutral”.

About 2.57M shares traded or 79.72% up from the average. Impax Laboratories Inc (NASDAQ:IPXL) has declined 49.01% since July 17, 2016 and is downtrending. It has underperformed by 65.71% the S&P500.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The company has market cap of $1.33 billion. The Firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products , in addition to the development and marketing of branded products. It currently has negative earnings. The Company’s divisions include Impax Generics and Impax Specialty Pharma.

More important recent Impax Laboratories Inc (NASDAQ:IPXL) news were published by: Prnewswire.com which released: “Impax Announces FDA Approval and Launch of Additional Strengths of Generic …” on July 05, 2017, also Prnewswire.com published article titled: “Impax to Report Second Quarter 2017 Results on August 9, 2017”, Thestreet.com published: “Biotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta” on July 17, 2017. More interesting news about Impax Laboratories Inc (NASDAQ:IPXL) was released by: Streetinsider.com and their article: “Impax Laboratories (IPXL) Receives FDA Approval for AB Rated Generic Concerta …” with publication date: July 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.